A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
NCT ID: NCT06614192
Last Updated: 2025-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
460 participants
INTERVENTIONAL
2024-11-08
2028-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Participants are put into treatment arms as part of 2 stages. Each treatment arm in stage 1 receives a different dose of telisotuzumab adizutecan. Each treatment arm in stage 2 receives the optimal dose of telisotuzumab adizutecan or LONSURF plus bevacizumab. Up to approximately 460 adult participants with c-Met protein above cutoff level refractory mCRC, will be enrolled in the study in approximately 160 sites in 15-20 countries.
In stage 1, participants will receive intravenously (IV) infused telisotuzumab adizutecan dose A or B. In stage 2, participants will receive the optimal dose of IV infused telisotuzumab adizutecan or the standard of care (SOC), LONSURF oral tablets plus IV infused bevacizumab. The total study duration will be approximately 4 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer
NCT06464692
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
NCT07023289
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
NCT04660812
Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer
NCT05869097
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
NCT06412198
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stage 1: Telisotuzumab Adizutecan Dose A
Participants will receive telisotuzumab adizutecan dose A, as part of the approximately 4 year study duration.
Telisotuzumab Adizutecan
Intravenous (IV) Infusion
Stage 1: Telisotuzumab Adizutecan Dose B
Participants will receive telisotuzumab adizutecan dose B, as part of the approximately 4 year study duration.
Telisotuzumab Adizutecan
Intravenous (IV) Infusion
Stage 2: Telisotuzumab Adizutecan Optimal Dose
Participants will receive the optimal dose of telisotuzumab adizutecan, as part of the approximately 4 year study duration.
Telisotuzumab Adizutecan
Intravenous (IV) Infusion
Stage 2: Standard of Care (SOC)
Participants will receive the SOC, as part of the approximately 4 year study duration.
Trifluridine/Tipiracil
Oral Tablet
Bevacizumab
IV Infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Telisotuzumab Adizutecan
Intravenous (IV) Infusion
Trifluridine/Tipiracil
Oral Tablet
Bevacizumab
IV Infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 during the screening period prior to the first dose of the study drug.
* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
Exclusion Criteria
* History of allergic reactions or hypersensitivity to bevacizumab or any of its excipients, or to compounds similar to trifluridine/tipiracil.
* Active infection as noted in the protocol.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope National Medical Center /ID# 267875
Duarte, California, United States
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 270655
Irvine, California, United States
USC Norris Comprehensive Cancer Center /ID# 268131
Los Angeles, California, United States
Lutheran Medical Center- Cancer Centers of Colorado /ID# 268175
Golden, Colorado, United States
Yale New Haven Hospital /ID# 269125
New Haven, Connecticut, United States
AdventHealth Orlando /ID# 267970
Orlando, Florida, United States
Winship Cancer Institute of Emory University /ID# 266884
Atlanta, Georgia, United States
St. Luke's Cancer Institute: Boise /ID# 268095
Boise, Idaho, United States
Northwestern Memorial Hospital /ID# 268610
Chicago, Illinois, United States
Hope And Healing Cancer Services /ID# 268541
Hinsdale, Illinois, United States
Springfield Clinic - First /ID# 268666
Springfield, Illinois, United States
Community Cancer Center North /ID# 267965
Indianapolis, Indiana, United States
Hattiesburg Clinic /ID# 267860
Hattiesburg, Mississippi, United States
Washington University /ID# 267872
St Louis, Missouri, United States
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 268185
Billings, Montana, United States
Rutgers Cancer Institute of New Jersey /ID# 268056
New Brunswick, New Jersey, United States
University of North Carolina Medical Center /ID# 266879
Chapel Hill, North Carolina, United States
Duke University Medical Center /ID# 267966
Durham, North Carolina, United States
Avera Cancer Institute - Sioux Falls /ID# 268074
Sioux Falls, South Dakota, United States
West Cancer Center and Research Institute - Germantown /ID# 268619
Germantown, Tennessee, United States
University of Texas - Southwestern Medical Center /ID# 268241
Dallas, Texas, United States
The University of Texas MD Anderson Cancer Center /ID# 268098
Houston, Texas, United States
Millennium Research & Clinical Development /ID# 268400
Houston, Texas, United States
University of Virginia /ID# 268108
Charlottesville, Virginia, United States
Mater Hospital Brisbane /ID# 268360
South Brisbane, Queensland, Australia
The Chaim Sheba Medical Center /ID# 267741
Ramat Gan, Tel Aviv, Israel
Tel Aviv Sourasky Medical Center /ID# 267578
Tel Aviv, Tel Aviv, Israel
Rambam Health Care Campus /ID# 267739
Haifa, , Israel
Hadassah Medical Center-Hebrew University /ID# 267579
Jerusalem, , Israel
Rabin Medical Center /ID# 267740
Petah Tikva, , Israel
Assuta Medical Center /ID# 267745
Tel Aviv, , Israel
Aichi Cancer Center /ID# 268237
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East /ID# 268236
Kashiwa-shi, Chiba, Japan
The University of Osaka Hospital /ID# 268743
Suita-shi, Osaka, Japan
Saitama Prefectural Cancer Center /ID# 268706
Kitaadachi-gun, Saitama, Japan
National Cancer Center Hospital /ID# 268713
Chuo-Ku, Tokyo, Japan
Pan American Center for Oncology Trials /ID# 267888
Rio Piedras, , Puerto Rico
Seoul National University Bundang Hospital /ID# 268592
Seongnam-si, Gyeonggido, South Korea
Seoul National University Hospital /ID# 268719
Seoul, Seoul Teugbyeolsi, South Korea
Yonsei University Health System Severance Hospital /ID# 268718
Seoul, Seoul Teugbyeolsi, South Korea
Asan Medical Center /ID# 268717
Seoul, Seoul Teugbyeolsi, South Korea
Samsung Medical Center /ID# 268720
Seoul, Seoul Teugbyeolsi, South Korea
Kaohsiung Chang Gung Memorial Hospital /ID# 267638
Kaohsiung City, Kaohsiung, Taiwan
National Taiwan University Hospital /ID# 267627
Taipei City, Taipei, Taiwan
Changhua Christian Hospital /ID# 270464
Changhua City, Changhua County, , Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 267635
Kaohsiung City, , Taiwan
China Medical University Hospital /ID# 267631
Taichung, , Taiwan
Taichung Veterans General Hospital /ID# 270467
Taichung, , Taiwan
National Cheng Kung University Hospital /ID# 270468
Tainan City, , Taiwan
Taipei Veterans General Hospital /ID# 267628
Taipei, , Taiwan
Linkou Chang Gung Memorial Hospital /ID# 267637
Taoyuan, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-512804-20-00
Identifier Type: OTHER
Identifier Source: secondary_id
M24-064
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.